Oral folic acid and vitamin B-12 supplementation to prevent cognitive decline in community-dwelling older adults with depressive symptoms - The Beyond Ageing Project

A randomized controlled trial

Janine G. Walker, Philip J. Batterham, Andrew J. Mackinnon, Anthony F. Jorm, Ian Hickie, Michael Fenech, Marjan Kljakovic, Dimity Crisp, Helen Christensen

Research output: Contribution to journalArticle

75 Citations (Scopus)

Abstract

Background: Evidence remains unclear as to whether folic acid (FA) and vitamin B-12 supplementation is effective in reducing depressive symptoms. Objectives: The objective was to determine whether oral FA + vitamin B-12 supplementation prevented cognitive decline in a cohort of community-dwelling older adults with elevated psychological distress. Design: A randomized controlled trial (RCT) with a completely crossed 2 x 2 x 2 factorial design comprising daily oral 400 μg FA + 100 μg vitamin B-12 supplementation (compared with placebo), physical activity promotion, and depression literacy with comparator control interventions for reducing depressive symptoms was conducted in 900 adults aged 60-74 y with elevated psychological distress (Kessler Distress 10-Scale; scores >15). The 2-y intervention was delivered in 10 modules via mail with concurrent telephone tracking calls. Main outcome measures examined change in cognitive functioning at 12 and 24 mo by using the Telephone Interview for Cognitive Status-Modified (TICS-M) and the Brief Test of Adult Cognition by Telephone (processing speed); the Informant Questionnaire on Cognitive Decline in the Elderly was administered at 24 mo. Results: FA + vitamin B-12 improved the TICS-M total (P = 0.032; effect size d = 0.17), TICS-M immediate (P = 0.046; d = 0.15), and TICS-M delayed recall (P = 0.013; effect size d = 0.18) scores at 24 mo in comparison with placebo. No significant changes were evident in orientation, attention, semantic memory, processing speed, or informant reports. Conclusion: Long-term supplementation of daily oral 400 μg FA + 100 μg vitamin B-12 promotes improvement in cognitive functioning after 24 mo, particularly in immediate and delayed memory performance. This trial was registered at clinicaltrials.gov as NCT00214682.

Original languageEnglish
Pages (from-to)194-203
Number of pages10
JournalAmerican Journal of Clinical Nutrition
Volume95
Issue number1
DOIs
Publication statusPublished - 1 Jan 2012
Externally publishedYes

Fingerprint

Independent Living
Vitamin B 12
Folic Acid
Randomized Controlled Trials
Depression
Interviews
Telephone
Placebos
Repression (Psychology)
Psychology
Postal Service
Short-Term Memory
Semantics
Cognition
Outcome Assessment (Health Care)
Cognitive Dysfunction
Exercise

Cite this

Walker, Janine G. ; Batterham, Philip J. ; Mackinnon, Andrew J. ; Jorm, Anthony F. ; Hickie, Ian ; Fenech, Michael ; Kljakovic, Marjan ; Crisp, Dimity ; Christensen, Helen. / Oral folic acid and vitamin B-12 supplementation to prevent cognitive decline in community-dwelling older adults with depressive symptoms - The Beyond Ageing Project : A randomized controlled trial. In: American Journal of Clinical Nutrition. 2012 ; Vol. 95, No. 1. pp. 194-203.
@article{0270ea4a17ea4377b6afdaa12f0cc108,
title = "Oral folic acid and vitamin B-12 supplementation to prevent cognitive decline in community-dwelling older adults with depressive symptoms - The Beyond Ageing Project: A randomized controlled trial",
abstract = "Background: Evidence remains unclear as to whether folic acid (FA) and vitamin B-12 supplementation is effective in reducing depressive symptoms. Objectives: The objective was to determine whether oral FA + vitamin B-12 supplementation prevented cognitive decline in a cohort of community-dwelling older adults with elevated psychological distress. Design: A randomized controlled trial (RCT) with a completely crossed 2 x 2 x 2 factorial design comprising daily oral 400 μg FA + 100 μg vitamin B-12 supplementation (compared with placebo), physical activity promotion, and depression literacy with comparator control interventions for reducing depressive symptoms was conducted in 900 adults aged 60-74 y with elevated psychological distress (Kessler Distress 10-Scale; scores >15). The 2-y intervention was delivered in 10 modules via mail with concurrent telephone tracking calls. Main outcome measures examined change in cognitive functioning at 12 and 24 mo by using the Telephone Interview for Cognitive Status-Modified (TICS-M) and the Brief Test of Adult Cognition by Telephone (processing speed); the Informant Questionnaire on Cognitive Decline in the Elderly was administered at 24 mo. Results: FA + vitamin B-12 improved the TICS-M total (P = 0.032; effect size d = 0.17), TICS-M immediate (P = 0.046; d = 0.15), and TICS-M delayed recall (P = 0.013; effect size d = 0.18) scores at 24 mo in comparison with placebo. No significant changes were evident in orientation, attention, semantic memory, processing speed, or informant reports. Conclusion: Long-term supplementation of daily oral 400 μg FA + 100 μg vitamin B-12 promotes improvement in cognitive functioning after 24 mo, particularly in immediate and delayed memory performance. This trial was registered at clinicaltrials.gov as NCT00214682.",
author = "Walker, {Janine G.} and Batterham, {Philip J.} and Mackinnon, {Andrew J.} and Jorm, {Anthony F.} and Ian Hickie and Michael Fenech and Marjan Kljakovic and Dimity Crisp and Helen Christensen",
year = "2012",
month = "1",
day = "1",
doi = "10.3945/ajcn.110.007799",
language = "English",
volume = "95",
pages = "194--203",
journal = "The Journal of clinical nutrition",
issn = "0002-9165",
publisher = "American Society for Nutrition",
number = "1",

}

Oral folic acid and vitamin B-12 supplementation to prevent cognitive decline in community-dwelling older adults with depressive symptoms - The Beyond Ageing Project : A randomized controlled trial. / Walker, Janine G.; Batterham, Philip J.; Mackinnon, Andrew J.; Jorm, Anthony F.; Hickie, Ian; Fenech, Michael; Kljakovic, Marjan; Crisp, Dimity; Christensen, Helen.

In: American Journal of Clinical Nutrition, Vol. 95, No. 1, 01.01.2012, p. 194-203.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Oral folic acid and vitamin B-12 supplementation to prevent cognitive decline in community-dwelling older adults with depressive symptoms - The Beyond Ageing Project

T2 - A randomized controlled trial

AU - Walker, Janine G.

AU - Batterham, Philip J.

AU - Mackinnon, Andrew J.

AU - Jorm, Anthony F.

AU - Hickie, Ian

AU - Fenech, Michael

AU - Kljakovic, Marjan

AU - Crisp, Dimity

AU - Christensen, Helen

PY - 2012/1/1

Y1 - 2012/1/1

N2 - Background: Evidence remains unclear as to whether folic acid (FA) and vitamin B-12 supplementation is effective in reducing depressive symptoms. Objectives: The objective was to determine whether oral FA + vitamin B-12 supplementation prevented cognitive decline in a cohort of community-dwelling older adults with elevated psychological distress. Design: A randomized controlled trial (RCT) with a completely crossed 2 x 2 x 2 factorial design comprising daily oral 400 μg FA + 100 μg vitamin B-12 supplementation (compared with placebo), physical activity promotion, and depression literacy with comparator control interventions for reducing depressive symptoms was conducted in 900 adults aged 60-74 y with elevated psychological distress (Kessler Distress 10-Scale; scores >15). The 2-y intervention was delivered in 10 modules via mail with concurrent telephone tracking calls. Main outcome measures examined change in cognitive functioning at 12 and 24 mo by using the Telephone Interview for Cognitive Status-Modified (TICS-M) and the Brief Test of Adult Cognition by Telephone (processing speed); the Informant Questionnaire on Cognitive Decline in the Elderly was administered at 24 mo. Results: FA + vitamin B-12 improved the TICS-M total (P = 0.032; effect size d = 0.17), TICS-M immediate (P = 0.046; d = 0.15), and TICS-M delayed recall (P = 0.013; effect size d = 0.18) scores at 24 mo in comparison with placebo. No significant changes were evident in orientation, attention, semantic memory, processing speed, or informant reports. Conclusion: Long-term supplementation of daily oral 400 μg FA + 100 μg vitamin B-12 promotes improvement in cognitive functioning after 24 mo, particularly in immediate and delayed memory performance. This trial was registered at clinicaltrials.gov as NCT00214682.

AB - Background: Evidence remains unclear as to whether folic acid (FA) and vitamin B-12 supplementation is effective in reducing depressive symptoms. Objectives: The objective was to determine whether oral FA + vitamin B-12 supplementation prevented cognitive decline in a cohort of community-dwelling older adults with elevated psychological distress. Design: A randomized controlled trial (RCT) with a completely crossed 2 x 2 x 2 factorial design comprising daily oral 400 μg FA + 100 μg vitamin B-12 supplementation (compared with placebo), physical activity promotion, and depression literacy with comparator control interventions for reducing depressive symptoms was conducted in 900 adults aged 60-74 y with elevated psychological distress (Kessler Distress 10-Scale; scores >15). The 2-y intervention was delivered in 10 modules via mail with concurrent telephone tracking calls. Main outcome measures examined change in cognitive functioning at 12 and 24 mo by using the Telephone Interview for Cognitive Status-Modified (TICS-M) and the Brief Test of Adult Cognition by Telephone (processing speed); the Informant Questionnaire on Cognitive Decline in the Elderly was administered at 24 mo. Results: FA + vitamin B-12 improved the TICS-M total (P = 0.032; effect size d = 0.17), TICS-M immediate (P = 0.046; d = 0.15), and TICS-M delayed recall (P = 0.013; effect size d = 0.18) scores at 24 mo in comparison with placebo. No significant changes were evident in orientation, attention, semantic memory, processing speed, or informant reports. Conclusion: Long-term supplementation of daily oral 400 μg FA + 100 μg vitamin B-12 promotes improvement in cognitive functioning after 24 mo, particularly in immediate and delayed memory performance. This trial was registered at clinicaltrials.gov as NCT00214682.

UR - http://www.scopus.com/inward/record.url?scp=84455188736&partnerID=8YFLogxK

U2 - 10.3945/ajcn.110.007799

DO - 10.3945/ajcn.110.007799

M3 - Article

VL - 95

SP - 194

EP - 203

JO - The Journal of clinical nutrition

JF - The Journal of clinical nutrition

SN - 0002-9165

IS - 1

ER -